Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03808558 |
Recruitment Status :
Recruiting
First Posted : January 17, 2019
Last Update Posted : December 20, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
KRAS Gene Mutation | Drug: TVB-2640 | Phase 2 |
Patients with stable disease or partial/complete remissions will continue therapy.
The endpoints are response rate-RR, disease control rate-DCR, PFS-progression-free survival, CTCAEv5.0 toxicities, plasma lipid levels, collection of sebaceous secretion via Sebutape, and 11C-acetate PET tumor imaging.
In the first stage, 13 patients will be enrolled. If fewer than 2 patients achieve response, the study will be stopped. If 2 or more patients have a radiographic response, an additional 21 patients will be enrolled , for a total accrual of 34 patients.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 34 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas |
Actual Study Start Date : | September 11, 2019 |
Estimated Primary Completion Date : | December 1, 2024 |
Estimated Study Completion Date : | December 1, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: TVB-2640
Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
|
Drug: TVB-2640
TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks. |
- Disease control rate of TVB-2640 [ Time Frame: every 8 weeks through study completion, an average of 1 year ]Determine Disease control rate of TVB-2640 in KRAS mutant NSCLC patients through RECIST and toxicity profile.
- Response rate of TVB-2640 [ Time Frame: every 8 weeks through study completion, an average of 1 year ]Determine response rate of TVB-2640 in KRAS mutant NSCLC patients through RECIST and toxicity profile.
- Safety profile of TVB-2640 [ Time Frame: Pretreatment and four weeks of treatment. ]Secondary endpoints are 11C-acetate tumor uptake pretreatment and at four weeks of treatment and plasma lipidomics pretreatment and at four weeks of treatment.
- Establish the predictive value of 11C-acetate PET [ Time Frame: Pretreatment and four weeks of treatment. ]To establish the predictive value of 11C-acetate PET pretreatment and post-treatment tumor uptake for disease control rate and response rate
- Mean change in fasting plasma lipidomics [ Time Frame: Pretreatment and four weeks of treatment. ]Blood samples for fasting plasma lipidomics will be collected at baseline and four weeks of treatment.
- Mean change in sebaceous secretion of fatty acids [ Time Frame: Pretreatment and four weeks of treatment. ]Sebutabe collection of sebaceous secretion of fatty acids will be performed at baseline and four weeks of treatment
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion:
-
Metastatic or advanced stage, histologically or cytologically confirmed NSCLC and molecular identification of oncogenic KRAS mutation.
- KRAS mutant NSCLC must be refractory, relapsed, and previously treated with doublet chemotherapy and immune checkpoint inhibitor (unless there is a specific contraindication to checkpoint inhibitor).
- Molecular characterization (tissue- or blood-based [ie, cell-free/circulating tumor DNA]) must have been performed and must have demonstrated an oncogenic KRAS mutation (e.g., exon 12, 13, 61, or 117 mutation detected by sequencing) by a CLIA-certified assay (source documentation required). KRAS mutations at other codons require review and approval by Study Chair.
- Subjects' EGFR mutation and ALK gene rearrangement status must be known prior to study entry. Subjects with EGFR mutation or ALK gene rearrangement must have progressed after appropriate FDA-approved targeted therapy options prior to eligibility.
- Patient has evidence of disease progression on most recent line of therapy.
- Patient has measurable disease by RECIST v1.1 (Eisenhauer, 2009).
- Age ≥ 18 years.
- ECOG performance status of 0 or 1.
- Predicted life expectancy of >3 months.
-
Adequate organ and marrow function as defined below:
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 75,000/mcL
- total bilirubin <2X institutional upper limit of normal
- AST and ALT ≤5X institutional upper limit of normal
- serum creatinine <1.5X institutional upper limit of normal
- LVEF >50%
- QTcF <470msec
-
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
-
A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
-
- No significant ischemic heart disease or myocardial infarction within 6 months of first dose of TVB-2640 and with current adequate cardiac function as in 3.1.8.
- Ability to understand and the willingness to sign a written informed consent.
Exclusion:
- Patient is unable to swallow oral medications or has impairment of GI function or GI disease that may significantly alter drug absorption such as active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome.
- Patient has a history of risk factors for torsade de pointes such as uncontrolled heart failure, severe hypokalemia with potassium less than 3mM/L, history of long QT syndrome or require use during study participation of concomitant medications known to prolong QT/QTc interval.
- Patients who require use of strong CYP3A4/5 agonists or inhibitors during study participation.
- Patient has uncontrolled or severe intercurrent medical condition including uncontrolled brain metastases. Patients with stable brain metastases either treated or untreated, on a stable dose of steroids/anticonvulsants, with no dose increase within 4 weeks before the first dose of TVB-2640, and no anticipated dose change, are allowed.
- Patient underwent major surgery within 4 weeks before the first dose of TVB-2640 or received cancer-directed therapy either chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc. or an investigational drug or device within 2 weeks (6 weeks for mitomycin C and nitrosoureas) or 5 half-lives of that agent, whichever is shorter before the first dose of TVB-2640. In addition, any drug- related toxicity, with the exception of alopecia, an endocrinopathy controlled with replacement therapy, or a clinically stable toxicity not expected to increase from study therapy (eg, cisplatin-associated ototoxicity) should have recovered to <Grade 1.
- If female, patient is pregnant or breast-feeding.
- Patient has evidence of a serious active infection-infection requiring treatment with intravenous antibiotics.
- Patient has known immunodeficiency virus-HIV or hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment and disease-related symptoms may preclude accurate assessment of the safety of TVB-2640.
- Patient has an important medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study.
- Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational agent.
- History of clinically significant dry eye (xerophthalmia) or other corneal abnormality or, if a contact lens wearer, does not agree to abstain from contact lens use from baseline through the last study drug dose.
- Patient has a known allergy or hypersensitivity to components of TVB-2640.
- Patient has a prior history of hypersensitivity, drug/radiation-induced, or other immune-mediated pneumonitis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03808558
Contact: Ebele Mbanugo, PhD | 214-648-7097 | Ebele.mbanugo@UTSouthwestern.edu | |
Contact: David Gerber, MD | david.gerber@utsouthwestern.edu |
United States, Ohio | |
University of Cincinnati | Recruiting |
Cincinnati, Ohio, United States, 45267 | |
Contact: UCCC Clinical Trials Office 513-584-7698 Cancer@UCHealth.com | |
United States, Texas | |
University of Texas Southwestern Medical Center | Recruiting |
Dallas, Texas, United States, 75390-9179 | |
Contact: David Gerber, MD 214-648-4180 David.Gerber@utsouthwestern.edu | |
Principal Investigator: David Gerber, MD |
Principal Investigator: | David Gerber, MD | Professor |
Responsible Party: | David E Gerber, PROFESSOR - Internal Medicine, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT03808558 |
Other Study ID Numbers: |
STU 022017-058 |
First Posted: | January 17, 2019 Key Record Dates |
Last Update Posted: | December 20, 2023 |
Last Verified: | December 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms |
Neoplasms by Site Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |